{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:17:13Z","timestamp":1788358633649,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Current guidelines for changing antiviral therapy regimens do not consider different baseline statuses. This study aimed to investigate whether significant prognostic differences exist among patients achieving virological response at various time points and whether these differences vary by viral load and HBeAg status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included 1,037 patients, who were classified based on their baseline viral load (high viral load, HVL, \u2265 7log<jats:sub>10<\/jats:sub> IU mL<jats:sup>\u22121<\/jats:sup>: 522 individuals; or non-HVL, &amp;lt; 7log<jats:sub>10<\/jats:sub> IU mL<jats:sup>\u22121<\/jats:sup>: 515 individuals) and HBeAg status (positive: 668 individuals; or negative: 369 individuals). Based on the virological response time, patients were grouped separately using 48 weeks and 96 weeks as the boundaries. The prognoses across these groups were evaluated and compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients in the within-48-week group, 48\u201396-week group, and after-96-week group exhibited no significant difference in the incidence of liver disease progression (5.08% vs 4.38% vs 9.61%, <jats:italic>p<\/jats:italic> = 0.33). For HVL or HBeAg-positive patients, there was no significant difference in the cumulative incidence of liver disease progression between the within-48-week group and the 48\u201396-week group. In contrast, for non-HVL or HBeAg-negative patients, the cumulative incidence of liver disease progression was significantly higher in the after-48-week group than in the within-48-week group. Only the after-96-week group showed a significant increase in maintained virological response rate (<jats:italic>p<\/jats:italic> = 0.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Antiviral treatment should be adjusted at 48 weeks for non-HVL or HBeAg-negative patients. For HVL and HBeAg-positive patients, we suggest changing the antiviral treatment plan to 96 weeks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1572827","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:11:48Z","timestamp":1745467908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Relationship Between Nucleos(t)ide analogue antiviral response time and prognosis in Chronic Hepatitis B: conclusions depend on baseline viral load and HBeAg status"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingtao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1756284818786108","DOI":"10.1177\/1756284818786108","article-title":"Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence","volume":"11","author":"Byrne","year":"2018","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B2","first-page":"2467","article-title":"Comparison of tenofovir and entecavir in patients with chronic HBV infection","volume":"17","author":"Ceylan","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/HEP.0000000000000752","article-title":"Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients","volume":"80","author":"Choi","year":"2024","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/liv.12694","article-title":"Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (\u22659 log10 copies\/ml)","volume":"35","author":"Fung","year":"2015","journal-title":"Liver Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MCG.0000000000000345","article-title":"Treatment outcomes with first-line therapies with entecavir and tenofovir in treatment-naive chronic hepatitis B patients in a routine clinical practice","volume":"50","author":"Ha","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1055\/s-2006-939751","article-title":"Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment","volume":"26","author":"Hadziyannis","year":"2006","journal-title":"Semin. Liver Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jvh.12313","article-title":"Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial","volume":"22","author":"Hou","year":"2015","journal-title":"J. Viral Hepat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.cgh.2018.04.063","article-title":"Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis","volume":"16","author":"Jang","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clinre.2017.06.008","article-title":"A long-term multicenter study: entecavir versus tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients","volume":"42","author":"Kayaaslan","year":"2018","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3969\/j.issn.1674-7380.2019.04.013","article-title":"Influencing factors of partial virological response to entecavir monotherapy of patients with chronic hepatitis B","volume":"11","author":"Li","year":"2019","journal-title":"Chin. J. Liver Dis. Electron. Version"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/liv.12343","article-title":"HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D","volume":"34","author":"Liu","year":"2014","journal-title":"Liver Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","article-title":"Randomised clinical trial: 48\u00a0weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B","volume":"54","author":"Liu","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3760\/cma.j.issn.1007-3418.2019.01.006","article-title":"Guideline for diagnosis and treatment of liver failure","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jcpt.12023","article-title":"Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers","volume":"38","author":"Lu","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8308","DOI":"10.1128\/JVI.00833-10","article-title":"Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection","volume":"84","author":"Mason","year":"2010","journal-title":"J. Virol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/jvh.12838","article-title":"Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B","volume":"25","author":"Nam","year":"2018","journal-title":"J. Viral Hepat."},{"key":"B21","article-title":"Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections. (2022\u20132030): report on Progress and Gaps 2024","year":"2024","journal-title":"Glob. HIV, Hepat. STIs Programmes (HHS)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/v13020180","article-title":"Hepatitis B virus DNA integration: in vitro models for investigating viral pathogenesis and persistence","volume":"13","author":"Tu","year":"2021","journal-title":"Viruses"},{"key":"B24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clinre.2014.09.009","article-title":"Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load","volume":"39","author":"Yan","year":"2015","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/JCTH.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B. Version 2022","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.14218\/JCTH.2021.00046","article-title":"Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ejca.2010.02.005","article-title":"Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis","volume":"46","author":"Zhou","year":"2010","journal-title":"Eur. J. Cancer."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1572827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:11:52Z","timestamp":1745467912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1572827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1572827"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1572827","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"article-number":"1572827"}}